Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Consolidated Net Income (2020 - 2022)

Historic Consolidated Net Income for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to -$34.4 million.

  • Atea Pharmaceuticals' Consolidated Net Income fell 12939.5% to -$34.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$115.9 million, marking a year-over-year decrease of 19564.24%. This contributed to the annual value of -$168.4 million for FY2024, which is 2385.26% down from last year.
  • Atea Pharmaceuticals' Consolidated Net Income amounted to -$34.4 million in Q4 2022, which was down 12939.5% from -$8.1 million recorded in Q3 2022.
  • Over the past 5 years, Atea Pharmaceuticals' Consolidated Net Income peaked at $117.1 million during Q4 2021, and registered a low of -$42.1 million during Q1 2022.
  • Moreover, its 3-year median value for Consolidated Net Income was -$10.0 million (2020), whereas its average is -$152545.5.
  • As far as peak fluctuations go, Atea Pharmaceuticals' Consolidated Net Income skyrocketed by 46706.04% in 2021, and later crashed by 213606.24% in 2022.
  • Atea Pharmaceuticals' Consolidated Net Income (Quarter) stood at $20.7 million in 2020, then surged by 467.06% to $117.1 million in 2021, then crashed by 129.4% to -$34.4 million in 2022.
  • Its last three reported values are -$34.4 million in Q4 2022, -$8.1 million for Q3 2022, and -$31.3 million during Q2 2022.